Circ Cardiovasc Interv:PCI术前肌钙蛋白T升高的稳定性CAD患者,死亡风险增加

2016-07-12 Seven L 译 MedSci原创

新研究表明,四分之一的稳定型冠心病(CAD)患者在择期PCI术前,其高敏肌钙蛋白T的水平升高,而这与患者的1年死亡风险的增加有关。研究人员对2029例稳定CAD患者进行了研究,在基线水平(PCI术前最多6小时)和PCI术后12小时,检测了患者的高灵敏度的心肌肌钙蛋白T浓度,在出院和整个1年对患者进行随访, 评估主要的不良心脑血管事件。总体而言,26%的患者术前高敏肌钙蛋白T高于上限14 ng/L;

新研究表明,四分之一的稳定型冠心病(CAD)患者在择期PCI术前,其高敏肌钙蛋白T的水平升高,而这与患者的1年死亡风险的增加有关。

研究人员对2029例稳定CAD患者进行了研究,在基线水平(PCI术前最多6小时)和PCI术后12小时,检测了患者的高灵敏度的心肌肌钙蛋白T浓度,在出院和整个1年对患者进行随访, 评估主要的不良心脑血管事件。

总体而言,26%的患者术前高敏肌钙蛋白T高于上限14 ng/L;其中大部分患者(84%)基线高敏肌钙蛋白T是参考上限的一倍到三倍之间。

PCI术前肌钙蛋白T升高组和正常组相比,1年全因死亡率分别为7.7%和1.4%(P < .001)。分析显示,术前高敏肌钙蛋白T升高的患者,PCI术后全因死亡风险更高(HR = 6.69; 95% CI, 1.73-25.87),心脏病死亡风险更高(HR = 5.73; 95% CI, 1.05-31.3)。术前高敏肌钙蛋白T升高也与术后BARC 3-5出血风险增加相关(HR = 2; 95% CI, 1.04-3.86)。

校正年龄、性别和肾功能衰竭等混杂因素后,术前高敏肌钙蛋白T升高是PCI术后全因死亡率的独立危险因素(aHR = 2.08; 95% CI, 1.1-3.92),但不是心脏死亡率的独立预测因素。

术前高敏肌钙蛋白T水平正常的患者(n = 1,502)进行分析,没有发现术前高敏肌钙蛋白T≤ 14 ng/L与全因死亡率间的关系(P = .41)。

研究人员认为,对择期行冠状动脉介入治疗的非急性冠状动脉综合征患者,进行高敏肌钙蛋白T的常规测量,将有助于完善风险分层。

原始出处:

Zanchin T, et al. Preprocedural High-Sensitivity Cardiac Troponin T and Clinical Outcomes in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention .Circ Cardiovasc Interv. 2016;doi:10.1161/CIRCINTERVENTIONS.115.003202.

High troponin observed in one quarter of patients with stable CAD before PCI.
Healio.July 11, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1900436, encodeId=a45e1900436ca, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Jan 22 14:44:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633825, encodeId=b5bb1633825da, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sun Jan 29 05:44:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938611, encodeId=8dbf193861107, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue May 16 17:44:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146934, encodeId=8c1d14693442, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Wed Oct 12 16:10:44 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122090, encodeId=eb96122090d9, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:57:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255574, encodeId=628812555e495, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569114, encodeId=3fb11569114d2, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1900436, encodeId=a45e1900436ca, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Jan 22 14:44:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633825, encodeId=b5bb1633825da, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sun Jan 29 05:44:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938611, encodeId=8dbf193861107, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue May 16 17:44:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146934, encodeId=8c1d14693442, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Wed Oct 12 16:10:44 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122090, encodeId=eb96122090d9, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:57:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255574, encodeId=628812555e495, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569114, encodeId=3fb11569114d2, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
    2017-01-29 zxl736
  3. [GetPortalCommentsPageByObjectIdResponse(id=1900436, encodeId=a45e1900436ca, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Jan 22 14:44:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633825, encodeId=b5bb1633825da, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sun Jan 29 05:44:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938611, encodeId=8dbf193861107, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue May 16 17:44:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146934, encodeId=8c1d14693442, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Wed Oct 12 16:10:44 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122090, encodeId=eb96122090d9, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:57:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255574, encodeId=628812555e495, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569114, encodeId=3fb11569114d2, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
    2017-05-16 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=1900436, encodeId=a45e1900436ca, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Jan 22 14:44:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633825, encodeId=b5bb1633825da, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sun Jan 29 05:44:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938611, encodeId=8dbf193861107, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue May 16 17:44:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146934, encodeId=8c1d14693442, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Wed Oct 12 16:10:44 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122090, encodeId=eb96122090d9, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:57:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255574, encodeId=628812555e495, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569114, encodeId=3fb11569114d2, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
    2016-10-12 1e0ece0dm09(暂无匿称)

    谢谢分享学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1900436, encodeId=a45e1900436ca, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Jan 22 14:44:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633825, encodeId=b5bb1633825da, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sun Jan 29 05:44:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938611, encodeId=8dbf193861107, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue May 16 17:44:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146934, encodeId=8c1d14693442, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Wed Oct 12 16:10:44 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122090, encodeId=eb96122090d9, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:57:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255574, encodeId=628812555e495, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569114, encodeId=3fb11569114d2, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
    2016-09-11 1e10c84am36(暂无匿称)

    己拜读,受益匪浅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1900436, encodeId=a45e1900436ca, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Jan 22 14:44:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633825, encodeId=b5bb1633825da, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sun Jan 29 05:44:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938611, encodeId=8dbf193861107, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue May 16 17:44:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146934, encodeId=8c1d14693442, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Wed Oct 12 16:10:44 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122090, encodeId=eb96122090d9, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:57:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255574, encodeId=628812555e495, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569114, encodeId=3fb11569114d2, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1900436, encodeId=a45e1900436ca, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Jan 22 14:44:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633825, encodeId=b5bb1633825da, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Sun Jan 29 05:44:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938611, encodeId=8dbf193861107, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue May 16 17:44:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146934, encodeId=8c1d14693442, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Wed Oct 12 16:10:44 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122090, encodeId=eb96122090d9, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:57:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255574, encodeId=628812555e495, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569114, encodeId=3fb11569114d2, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Thu Jul 14 03:44:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]

相关资讯

血管竟然可以这样疏通!!!

导语:点播放后,根本停不下来。 点击图片,即可跳转进入视频观看界面,请处于WiFi条件下观看,土豪随意。

WICCVD 2016:董念国——冠脉外科若干热点问题

2016年6月25日,由华中科技大学同济医学院附属协和医院主办的第三届武汉国际心血管病大会在武汉举行。冠心病外科治疗策略、技术、效果,一直是心血管外科关注热点,为此本届大会执行主席、华中科技大学同济医学院附属协和医院心脏大血管外科主任董念国教授在大会做了题为《冠脉外科若干热点问题》的学术报告,以下是详细内容:在介绍热点问题之前,董教授首先介绍了冠心病治疗发展的国内外趋势:国外趋势:以日本为例,

Circ Cardiovasc Interv:PCI治疗放射相关CAD的死亡率研究

与标准的动脉粥样硬化性冠心病(CAD)患者相比,既往外照射治疗的CAD患者进行冠状动脉冠状动脉介入术(PCI)后,其短期和长期的死亡风险均增加。克利夫兰诊所心脏和血管研究所的Milind Y. Desai博士和同事对314名连续PCI治疗的患者进行了观察性研究。患者分两组:体外放射治疗的CAD组(EBRT;n = 157)和以前没有EBRT曝光的CAD患者(对照组;n = 157)。研究以全因死亡

2016ACC:值得关注的STEMI治疗领域重磅研究

2016年美国心脏病学会(ACC)科学年会已于4月2~4日在美国芝加哥成功召开。本文对在该大会上公布的STEMI治疗领域的最新研究进展进行了汇总。

中国PCI指南六大更新:稳定冠心病患者狭窄<90%,干预时需要有缺血证据

近日,《中国经皮冠状动脉介入治疗指南(2016)》发布。

PCI术中辅助支架精准定位的新方法—漂浮导丝和漂浮球囊技术

作者:李悦 公永太 孙党辉  哈尔滨医科大学附属第一医院PCI术中支架释放时保持支架位置稳定对于冠状动脉开口病变、分叉病变或其他需要支架精准定位释放的病变尤为重要。但有时由于心脏搏动可引起支架较大幅度位置移动,使支架精准定位释放困难,可能导致病变覆盖不完全、无病变节段或分支被支架覆盖等不良后果,严重者需置入另一枚支架补救,加重患者经济负担,且增加支架内血栓和再狭窄风险。 支架定位过程中